GlassScriptPhysician profile
Anastasiya Kleva
NPI 1841515855
$5,058.66
in general payments reported to CMS, 2019-2025
27 companies · $1,114 in 2025
The $1,114 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $329 · 2022: $749 · 2023: $1,307 · 2024: $1,029 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,361 · Education: $88.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.80 |
| Education | $88.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,102.42 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,027.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $853.23 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Novartis Pharmaceuticals Corporation | $518.51 | 2019-2025 | |
| Optinose US, INC. | $366.17 | 2019-2025 | |
| Amgen INC. | $217.61 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $103.54 | 2023-2025 | Dupixent |
| Stryker Corporation | $92.01 | 2019-2025 | Scopis Ent |
| Alk-Abello, INC | $85.80 | 2019 | |
| Genentech USA, INC. | $85.29 | 2019-2023 | Xolair |
| Inspire Medical Systems, INC. | $84.46 | 2023-2025 | Inspire |
| Kaleo, INC. | $64.06 | 2024 | Auvi-Q |
| Integra Lifesciences Corporation | $60.70 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Pfizer INC. | $45.36 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $40.00 | 2023 | Ryaltris |
| Leo Pharma INC. | $39.70 | 2025 | Adbry, Anzupgo |
| Acclarent, INC | $35.53 | 2020 | |
| Incyte Corporation | $28.53 | 2025 | Opzelura |
| Aytu Biopharma, INC. | $24.98 | 2025 | |
| Neurent Medical Limited | $23.46 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Intersect Ent, INC. | $21.04 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.77 | 2025 | Xhance |
| Teva Pharmaceuticals USA, INC. | $20.00 | 2020 | |
| Merck Sharp & Dohme LLC | $17.53 | 2023 | |
| Arbor Pharmaceuticals, INC. | $13.33 | 2019 | |
| Abbvie INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anastasiya Kleva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.